Dr. Linas is a national leader in hepatitis-C virus (HCV) infection and HCV/HIV co-infection comparative- and cost-effectiveness research using computational biology, clinical epidemiology and clinical economics methods. Dr. Linas has an excellent track record of productivity, ample funding from the NIH and CDC, and a growing core of successful trainees. Dr. Linas directs the HIV/HCV core of the Center for Health Economics of Treatment Interventions for Substance Use Disorders, HCV, and HIV, funded by the National Institute on Drug Abuse (NIDA) in collaboration with Cornell, U Penn and Miami.
- Associate Professor, Epidemiology, Boston University School of Public Health
- New York University School of Medicine, MD
- Harvard School of Public Health, MPH
- Yale University, BA
- Published on 12/10/2019
Epstein RL, Wang J, Hagan L, Mayer KH, Puro J, Linas BP, Assoumou SA. Hepatitis C Virus Antibody Testing Among 13- to 21-Year-Olds in a Large Sample of US Federally Qualified Health Centers. JAMA. 2019 12 10; 322(22):2245-2248. PMID: 31821424.
- Published on 12/9/2019
Ghany MG, Marks KM, Morgan TR, Wyles DL, Aronsohn AI, Bhattacharya D, Broder T, Falade-Nwulia OO, Feld JJ, Gordon SC, Heller T, Jhaveri RR, Jonas MM, Kiser JJ, Linas BP, Lo Re V, Peters MG, Reddy KR, Reynolds A, Scott JD, Searson G, Spradling P, Terrault NA, Trooskin SB, Verna EC, Wong JB, Woolley AE, Workowski KA. Hepatitis C Guidance 2019 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Hepatology. 2019 Dec 09. PMID: 31816111.
- Published on 11/15/2019
Bellerose M, Zhu L, Hagan LM, Thompson WW, Randall LM, Malyuta Y, Salomon JA, Linas BP. A review of network simulation models of hepatitis C virus and HIV among people who inject drugs. Int J Drug Policy. 2019 Nov 15; 102580. PMID: 31740175.
- Published on 10/10/2019
Kimmel SD, Walley AY, Linas BP, Kalesan B, Awtry E, Dobrilovic N, White L, LaRochelle M. Effect of Publicly Reported Aortic Valve Surgery Outcomes on Valve Surgery in Injection Drug- and Non-Injection Drug-Associated Endocarditis. Clin Infect Dis. 2019 Oct 10. PMID: 31598642.
- Published on 7/3/2019
Linas BP. The 340B System-A Paradox Revealed. JAMA Netw Open. 2019 Jul 03; 2(7):e196537. PMID: 31276173.
- Published on 5/16/2019
Assoumou SA, Tasillo A, Vellozzi C, Yazdi GE, Wang J, Nolen S, Hagan L, Thompson W, Randall LM, Strick L, Salomon JA, Linas BP. Cost-effectiveness and budgetary impact of HCV testing, treatment and linkage to care in U.S. prisons. Clin Infect Dis. 2019 May 16. PMID: 31095676.
- Published on 5/16/2019
Gutkind S, Schackman BR, Morgan JR, Leff JA, Agyemang L, Murphy SM, Akiyama MJ, Norton BL, Litwin AH, Linas BP. Cost-effectiveness of HCV Treatment Models for People Who Inject Drugs in Opioid Agonist Treatment Programs. Clin Infect Dis. 2019 May 16. PMID: 31095683.
- Published on 5/10/2019
Barocas JA, Morgan JR, Fiellin DA, Schackman BR, Eftekhari Yazdi G, Stein MD, Freedberg KA, Linas BP. Cost-effectiveness of integrating buprenorphine-naloxone treatment for opioid use disorder into clinical care for persons with HIV/hepatitis C co-infection who inject opioids. Int J Drug Policy. 2019 10; 72:160-168. PMID: 31085063.
- Published on 5/8/2019
Barocas JA, Wang J, Marshall BDL, LaRochelle MR, Bettano A, Bernson D, Beckwith CG, Linas BP, Walley AY. Sociodemographic factors and social determinants associated with toxicology confirmed polysubstance opioid-related deaths. Drug Alcohol Depend. 2019 07 01; 200:59-63. PMID: 31100636.
- Published on 5/3/2019
Morgan JR, Schackman BR, Weinstein ZM, Walley AY, Linas BP. Overdose following initiation of naltrexone and buprenorphine medication treatment for opioid use disorder in a United States commercially insured cohort. Drug Alcohol Depend. 2019 07 01; 200:34-39. PMID: 31082666.
View 78 more publications: View full profile at BUMC